{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T19:03:11Z","timestamp":1793473391123,"version":"4.5.0"},"reference-count":52,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T00:00:00Z","timestamp":1657152000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005089","name":"Beijing Municipal Natural Science Foundation","doi-asserted-by":"publisher","award":["J200015, 7204328"],"award-info":[{"award-number":["J200015, 7204328"]}],"id":[{"id":"10.13039\/501100005089","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>\n                    Senescent T cells are reported to be increased in patients with cancer and are poor prognostic indicators. However, the distribution of senescent T cells and their correlation with clinical features in high-grade serous ovarian cancer (HGSOC) is unknown. We detected the percentage of senescent T cells in the peripheral blood and ascites of patients with advanced HGSOC (n = 86) at diagnosis by flow cytometry. Compared with healthy donors, patients with HGSOC exhibited an accumulation of CD28\n                    <jats:sup>\u2212<\/jats:sup>\n                    CD57\n                    <jats:sup>+<\/jats:sup>\n                    (Tsen) CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cells in the peripheral blood and ascites. The frequency of Tsen CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cells in the peripheral blood was positively correlated with age and pretreatment serum CA125 and increased in patients with large volume ascites, whereas the frequency of Tsen CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cells in ascites was elevated in patients with lymph node metastasis. Patients with Tsen-high in ascites (&amp;gt;19.92%), but not in the peripheral blood, were more likely to be resistant to chemotherapy and had shorter progression-free survival. Tsen CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cells exhibited common senescence features including increased SA-\u03b2-gal activity, declines in proliferation, loss of CD27 and gain of KLRG-1, and the production of cytokines. In ascites, the percentage of Tsen CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cells was positively correlated with levels of interleukin-10 and granzyme B. This study suggests the potential of ascitic Tsen CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cells at diagnosis as a prognostic biomarker in HGSOC.\n                  <\/jats:p>","DOI":"10.3389\/fonc.2022.864021","type":"journal-article","created":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T08:40:22Z","timestamp":1657183222000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["Ascitic Senescent T Cells Are Linked to Chemoresistance in Patients With Advanced High-Grade Serous Ovarian Cancer"],"prefix":"10.3389","volume":"12","author":[{"given":"Jie","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianhui","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongnan","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunliang","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixiang","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,7,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32552-2","article-title":"Epithelial Ovarian Cancer","volume":"393","author":"Lheureux","year":"2019","journal-title":"Lancet (London England)"},{"key":"B2","doi-asserted-by":"publisher","first-page":"9","DOI":"10.20892\/j.issn.2095-3941.2016.0084","article-title":"Epidemiology of Ovarian Cancer: A Review","volume":"14","author":"Reid","year":"2017","journal-title":"Cancer Biol Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"iv259","DOI":"10.1093\/annonc\/mdy157","article-title":"Newly Diagnosed and Relapsed Epithelial Ovarian Carcinoma: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up","author":"Ledermann","year":"2018","journal-title":"Ann Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41416-020-0875-x","article-title":"The Untapped Potential of Ascites in Ovarian Cancer Research and Treatment","volume":"123","author":"Ford","year":"2020","journal-title":"Br J Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1424672","article-title":"Prognosis of Ovarian Cancer is Associated With Effector Memory CD8(+) T Cell Accumulation in Ascites, CXCL9 Levels and Activation-Triggered Signal Transduction in T Cells","volume":"7","author":"Lieber","year":"2018","journal-title":"Oncoimmunology"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1535730","article-title":"Immune Profiling and Identification of Prognostic Immune-Related Risk Factors in Human Ovarian Cancer","volume":"8","author":"R\u00e5destad","year":"2019","journal-title":"Oncoimmunology"},{"key":"B7","article-title":"Ovarian Cancer-Associated Ascites Demonstrates Altered Immune Environment: Implications for Antitumor Immunity","volume":"29","author":"Giuntoli","year":"2009","journal-title":"Anticancer Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2016.09.002","article-title":"Senescence of T Lymphocytes: Implications for Enhancing Human Immunity","volume":"37","author":"Akbar","year":"2016","journal-title":"Trends Immunol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"103409","DOI":"10.1016\/j.ebiom.2021.103409","article-title":"Senescent T Cells: A Potential Biomarker and Target for Cancer Therapy","volume":"68","author":"Zhang","year":"2021","journal-title":"EBioMedicine"},{"key":"B10","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/s13045-020-00986-z","article-title":"Immunosenescence: A Key Player in Cancer Development","volume":"13","author":"Lian","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001536","article-title":"Tumor-Derived ILT4 Induces T Cell Senescence and Suppresses Tumor Immunity","volume":"9","author":"Gao","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaz6314","article-title":"Reprogramming Lipid Metabolism Prevents Effector T Cell Senescence and Enhances Tumor Immunotherapy","volume":"13","author":"Liu","year":"2021","journal-title":"Sci Transl Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-008-0789-8","article-title":"Prognostic Value of CD57(+) T Lymphocytes in the Peripheral Blood of Patients With Advanced Gastric Cancer","volume":"13","author":"Akagi","year":"2008","journal-title":"Int J Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-013-1424-8","article-title":"Elevated Level of Peripheral CD8(+)CD28(-) T Lymphocytes are an Independent Predictor of Progression-Free Survival in Patients With Metastatic Breast Cancer During the Course of Chemotherapy","volume":"62","author":"Song","year":"2013","journal-title":"Cancer Immunol Immunother CII"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3003","article-title":"Characterization of Immune Dysfunction and Identification of Prognostic Immune-Related Risk Factors in Acute Myeloid Leukemia","volume":"26","author":"Tang","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B16","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1158\/1078-0432.CCR-20-1420","article-title":"Circulating T-Cell Immunosenescence in Patients With Advanced Non-Small Cell Lung Cancer Treated With Single-Agent PD-1\/PD-L1 Inhibitors or Platinum-Based Chemotherapy","volume":"27","author":"Ferrara","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/jrr\/rrs108","article-title":"Epithelial Ovarian Cancer: Definitive Radiotherapy for Limited Recurrence After Complete Remission had Been Achieved With Aggressive Front-Line Therapy","volume":"54","author":"Yahara","year":"2013","journal-title":"J Radiat Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx441","article-title":"Treatment of Recurrent Ovarian Cancer","volume":"28","author":"Pignata","year":"2017","journal-title":"Ann Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/jog.14682","article-title":"Relationship Between Ascites Volume and Clinical Outcomes in Epithelial Ovarian Cancer","volume":"47","author":"Quan","year":"2021","journal-title":"J Obstet Gynaecol Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-17-0336","article-title":"Biomarkers of Platinum Resistance in Ovarian Cancer: What can We Use to Improve Treatment","volume":"25","author":"van Zyl","year":"2018","journal-title":"Endocr Relat Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000639","article-title":"CD8(+)CD57(+) T Cells Exhibit Distinct Features in Human non-Small Cell Lung Cancer","volume":"8","author":"Huang","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01651","article-title":"Features of Immunosenescence in Women Newly Diagnosed With Breast Cancer","volume":"9","author":"Trintinaglia","year":"2018","journal-title":"Front Immunol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s00262-003-0395-6","article-title":"Rapid Turnover of the CD8(+)CD28(-) T-Cell Subset of Effector Cells in the Circulation of Patients With Head and Neck Cancer","volume":"52","author":"Tsukishiro","year":"2003","journal-title":"Cancer Immunol Immunother CII"},{"key":"B24","doi-asserted-by":"publisher","first-page":"395","DOI":"10.4049\/immunohorizons.2100008","article-title":"Aging- and Tumor-Mediated Increase in CD8(+)CD28(-) T Cells Might Impose a Strong Barrier to Success of Immunotherapy in Glioblastoma","volume":"5","author":"Huff","year":"2021","journal-title":"Immunohorizons"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.120974","article-title":"Signatures of CD8+ T Cell Dysfunction in AML Patients and Their Reversibility With Response to Chemotherapy","volume":"3","author":"Knaus","year":"2018","journal-title":"JCI Insight"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-2630","article-title":"Expansion of a CD8(+)PD-1(+) Replicative Senescence Phenotype in Early Stage CLL Patients is Associated With Inverted CD4:CD8 Ratios and Disease Progression","volume":"18","author":"Nunes","year":"2012","journal-title":"Clin Cancer Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.713132","article-title":"Polyfunctional KLRG-1(+)CD57(+) Senescent CD4(+) T Cells Infiltrate Tumors and Are Expanded in Peripheral Blood From Breast Cancer Patients","volume":"12","author":"Ramello","year":"2021","journal-title":"Front Immunol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1186\/s12967-019-2097-7","article-title":"Prognostic Significance of Peripheral CD8+CD28+ and CD8+CD28- T Cells in Advanced non-Small Cell Lung Cancer Patients Treated With Chemo(Radio)Therapy","volume":"17","author":"Liu","year":"2019","journal-title":"J Trans Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2021.03.008","article-title":"Impact of Age, Comorbidity, and Treatment Characteristics on Survival in Older Women With Advanced High Grade Epithelial Ovarian Cancer","volume":"161","author":"Mallen","year":"2021","journal-title":"Gynecol Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2018.08.003","article-title":"Impact of Human Cytomegalovirus Infection and its Immune Response on Survival of Patients With Ovarian Cancer","volume":"11","author":"R\u00e5destad","year":"2018","journal-title":"Transl Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2981","article-title":"The Kinase P38 Activated by the Metabolic Regulator AMPK and Scaffold TAB1 Drives the Senescence of Human T Cells","volume":"15","author":"Lanna","year":"2014","journal-title":"Nat Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-020-0643-3","article-title":"Sestrins Induce Natural Killer Function in Senescent-Like CD8(+) T Cells","volume":"21","author":"Pereira","year":"2020","journal-title":"Nat Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1302064","article-title":"Age-Related Decrease in TCR Repertoire Diversity Measured With Deep and Normalized Sequence Profiling","volume":"192","author":"Britanova","year":"2014","journal-title":"J Immunol (Baltimore Md 1950)"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1111\/acel.12675","article-title":"Human CD8(+) EMRA T Cells Display a Senescence-Associated Secretory Phenotype Regulated by P38 MAPK","volume":"17","author":"Callender","year":"2018","journal-title":"Aging Cell"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-19-0596","article-title":"Low-Dose Ifn\u03b3 Induces Tumor Cell Stemness in Tumor Microenvironment of Non-Small Cell Lung Cancer","volume":"79","author":"Song","year":"2019","journal-title":"Cancer Res"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00847","article-title":"Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion","volume":"9","author":"Castro","year":"2018","journal-title":"Front Immunol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/s41467-017-02689-5","article-title":"Regulatory T Cells Trigger Effector T Cell DNA Damage and Senescence Caused by Metabolic Competition","volume":"9","author":"Liu","year":"2018","journal-title":"Nat Commun"},{"key":"B38","doi-asserted-by":"publisher","first-page":"109445","DOI":"10.1016\/j.cellsig.2019.109445","article-title":"Interleukin-10 Induces Senescence of Activated Hepatic Stellate Cells via STAT3-P53 Pathway to Attenuate Liver Fibrosis","volume":"66","author":"Huang","year":"2020","journal-title":"Cell Signal"},{"key":"B39","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s13045-016-0345-3","article-title":"T Cells in Multiple Myeloma Display Features of Exhaustion and Senescence at the Tumor Site","volume":"9","author":"Zelle-Rieser","year":"2016","journal-title":"J Hematol Oncol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1186\/s12885-015-2013-3","article-title":"Shifts in Subsets of CD8+ T-Cells as Evidence of Immunosenescence in Patients With Cancers Affecting the Lungs: An Observational Case-Control Study","volume":"15","author":"Onyema","year":"2015","journal-title":"BMC Cancer"},{"key":"B41","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s00262-015-1773-6","article-title":"Biomarkers Related to Immunosenescence: Relationships With Therapy and Survival in Lung Cancer Patients","volume":"65","author":"Saavedra","year":"2016","journal-title":"Cancer Immunol Immunother CII"},{"key":"B42","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1186\/s40425-019-0825-4","article-title":"Chemotherapy Accelerates Immune-Senescence and Functional Impairments of V\u03b42(Pos) T Cells in Elderly Patients Affected by Liver Metastatic Colorectal Cancer","volume":"7","author":"Bruni","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22126532","article-title":"Ovarian Cancer Immunotherapy and Personalized Medicine","volume":"22","author":"Morand","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2018-000071","article-title":"Trials in Progress: IMagyn050\/GOG 3015\/ENGOT-OV39. A Phase III, Multicenter, Randomized Study of Atezolizumab Versus Placebo Administered in Combination With Paclitaxel, Carboplatin, and Bevacizumab to Patients With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","author":"Moore","year":"2019","journal-title":"Int J Gynecol Cancer"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz135","article-title":"Antitumor Activity and Safety of Pembrolizumab in Patients With Advanced Recurrent Ovarian Cancer: Results From the Phase II KEYNOTE-100 Study","volume":"30","author":"Matulonis","year":"2019","journal-title":"Ann Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2020.06.025","article-title":"Avelumab in Combination With and\/or Following Chemotherapy vs Chemotherapy Alone in Patients With Previously Untreated Epithelial Ovarian Cancer: Results From the Phase 3 Javelin Ovarian 100 Trial","volume":"159","author":"Ledermann","year":"2020","journal-title":"Gynecol Oncol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"6005","DOI":"10.1200\/JCO.2020.38.15_suppl.6005","article-title":"Final Results From the KEYNOTE-100 Trial of Pembrolizumab in Patients With Advanced Recurrent Ovarian Cancer","volume":"38","author":"Matulonis","year":"2020","journal-title":"J Clin Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.08.2261","article-title":"LBA31 Primary Results From IMagyn050\/GOG 3015\/ENGOT-OV39, a Double-Blind Placebo (Pbo)-Controlled Randomised Phase III Trial of Bevacizumab (Bev)-Containing Therapy +\/- Atezolizumab (Atezo) for Newly Diagnosed Stage III\/IV Ovarian Cancer (OC)","volume":"31","author":"Moore","year":"2020","journal-title":"Ann Oncol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf1292","article-title":"T Cell Costimulatory Receptor CD28 is a Primary Target for PD-1-Mediated Inhibition","volume":"355","author":"Hui","year":"2017","journal-title":"Sci (New York NY)"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf0683","article-title":"Rescue of Exhausted CD8 T Cells by PD-1-Targeted Therapies is CD28-Dependent","volume":"355","author":"Kamphorst","year":"2017","journal-title":"Sci (New York NY)"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-020-0427-6","article-title":"PD-1 Blockade-Unresponsive Human Tumor-Infiltrating CD8(+) T Cells are Marked by Loss of CD28 Expression and Rescued by IL-15","volume":"18","author":"Kim","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ejca.2016.12.011","article-title":"Peripheral CD8 Effector-Memory Type 1 T-Cells Correlate With Outcome in Ipilimumab-Treated Stage IV Melanoma Patients","volume":"73","author":"Wistuba-Hamprecht","year":"2017","journal-title":"Eur J Cancer (Oxford Engl 1990)"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.864021\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T08:40:27Z","timestamp":1657183227000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.864021\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,7]]},"references-count":52,"alternative-id":["10.3389\/fonc.2022.864021"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.864021","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,7]]},"article-number":"864021"}}